Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients — NEOpredict

NSCLC, Stage I Clinical Trial

Official title:
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response

Status Recruiting

Clinical Trial Summary

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04205552
Study type	Interventional
Source	University Hospital, Essen
Contact	Chiara Nicolini, PhD
Phone	0049 201 723 44708
Email	chiara.nicolini@uk-essen.de
Status	Recruiting
Phase	Phase 2
Start date	March 4, 2020
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05686434` - Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)	Phase 2
Recruiting	`NCT04317534` - Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm	Phase 2
Not yet recruiting	`NCT03446911` - Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery	Phase 1/Phase 2
Recruiting	`NCT04830826` - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting	`NCT03454685` - The Role of Microbiota on the Development of Lung Cancer
Enrolling by invitation	`NCT06028412` - Comparison of Segmentectomy and Lobectomy in Small (2 cm or Less 0.5<CTR<1) Non-small Cell Lung Cancer: a Prospective, Multicenter Randomized Controlled Study	N/A
Recruiting	`NCT03446547` - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)	Phase 2